–Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo. –Denifanstat (ASC40) demonstrated a favorable safety and tolerability profile. Treatment emergent adverse events (TEAEs) […]
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study’s 52-week extension The safety and tolerability profile […]
TUALATIN, Ore., Sept. 17, 2025 /PRNewswire/ — SAM Medical, a leading provider of pre-hospital emergency medical products, is pleased to announce the acquisition of TyTek Medical, part of the TyTek Group. TyTek Medical is a […]
Phase 2/3 Wave II Clinical Study to Begin in 2026 Completion of Financing to Support Registration Program MONTREAL, Sept. 17, 2025 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel serum glucocorticoid inducible […]
White paper shares best practices and reflections from leaders on how prioritizing patient safety strengthens organizational resilience WILLOW GROVE, Pa., Sept. 17, 2025 /PRNewswire/ — As pressures mount for health system leaders nationwide, ECRI convened […]
